KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with our first investigational product for hereditary angioedema (HAE), a rare genetic disease with unpredictable attacks of tissue swelling that can be life threatening.

our first
Focal Point — HAE

For more than a decade, KalVista has been focused on bringing scientific advances to address the unmet needs of the HAE community. Today, we have more than 130 employees worldwide who are deeply motivated to develop medicines that will meaningfully improve the everyday lives of patients with HAE.

Our first investigational product, sebetralstat, is an oral on-demand treatment for HAE that has achieved positive results in a pivotal Phase 3 clinical trial.

As an oral medication, sebetralstat is designed to offer an alternative to the complexities and treatment burden of currently approved HAE treatment options, which require injectable administration or chronic dosing.

Expands our vista

The innovations in our pipeline include preclinical programs for oral Factor XIIa inhibitors, expanding our HAE product portfolio to include prophylactic treatment of HAE, as well as pushing ahead with new treatments for other diseases, such as thrombosis and inflammation.

our TEAM